Nucoxia L1P Tablet

Important note: "Nucoxia L1P" does not appear in any standard national or international drug databases, official prescribing information, or major Indian pharmacy platforms (1mg, PharmEasy, Practo, Truemeds). It may be a regional/local brand variant, a batch-specific code, or a recently launched combination product with limited online documentation. The information below is based on the Nucoxia brand family and the known pharmacology of etoricoxib.

What is Nucoxia?

Etoricoxib - Key Pharmacology

• Class: Selective COX-2 inhibitor (coxib), NSAID
• Mechanism: Selectively blocks cyclooxygenase-2 (COX-2), the enzyme responsible for prostaglandin synthesis that mediates pain, swelling, and inflammation. Spares COX-1, which protects the gastric mucosa - this gives etoricoxib a better GI safety profile than non-selective NSAIDs.
• Selectivity: Second highest COX-2 selectivity among coxibs (after lumiracoxib)
• Bioavailability: ~80% after oral absorption
• Half-life (t½): 20-26 hours - allows once-daily dosing
• Metabolism: Extensively hepatic; patients with liver impairment are prone to drug accumulation
• Renal clearance: Renal insufficiency does not affect drug clearance

Therapeutic Indications

Side Effects

• Hypertension (notably more frequent/severe than some other NSAIDs)
• Peripheral edema / fluid retention
• Headache, dizziness
• GI complaints - abdominal pain, heartburn, nausea, dyspepsia

• Increased risk of myocardial infarction and stroke (dose- and duration-dependent)
• Congestive heart failure
• Atrial fibrillation
• Hypersensitivity reactions (angioedema, anaphylaxis)
• GI bleeding / peptic ulcer (lower risk than non-selective NSAIDs, but not zero)

Contraindications

• Active peptic ulcer / GI bleeding
• Severe hepatic impairment (Child-Pugh > 9)
• Established ischemic heart disease, peripheral artery disease, cerebrovascular disease
• Uncontrolled hypertension (BP persistently > 140/90 mmHg)
• Congestive heart failure (NYHA Class II-IV)
• Inflammatory bowel disease
• Allergy to NSAIDs or aspirin
• Age under 16 years
• Pregnancy (especially 3rd trimester) - UNSAFE

Special Populations

• Elderly: No dose adjustment needed, but caution advised
• Hepatic impairment (mild, Child-Pugh 5-6): Do not exceed 60 mg/day
• Hepatic impairment (moderate, Child-Pugh 7-9): 60 mg every other day or 30 mg/day
• Renal impairment: No dose adjustment required
• Pregnancy/Breastfeeding: Avoid; consult physician

Key Drug Interactions

• Lithium - etoricoxib increases lithium plasma levels; monitor closely
• Warfarin/anticoagulants - may affect INR; monitor prothrombin time
• ACE inhibitors / ARBs (e.g., Ramipril) - reduced antihypertensive effect; risk of acute kidney injury
• Rifampicin - induces etoricoxib metabolism; reduces efficacy
• Ethinyl estradiol - etoricoxib may increase estrogen plasma levels

If "Nucoxia L1P" was prescribed to you or a patient, please verify the exact composition from the physical tablet blister/strip, package insert, or the prescribing physician, as this specific variant is not documented in publicly accessible databases. The "L1P" code may indicate a hospital/institutional pack, a combination not yet listed online, or a regional labeling variant.